Abstract CT199: IMpower133: Primary efficacy and safety + CNS-related adverse events in a Ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2019-ct199
Abstract: Background Platinum chemotherapy (carboplatin or cisplatin) + etoposide is the current 1L standard of care treatment (tx) for ES-SCLC. Despite high response rates on this regimen, patient (pt) outcomes remain poor. IMpower133 is a Ph1/3,… read more here.
Keywords: carboplatin etoposide; efficacy; atezo carboplatin; sclc ... See more keywords